Breaking
AACR/ASCO Methods in Clinical 2026 PreviewJASCAYD (nerandomilast) Wins EU Approval for IPF & PPFVanda: EMA Positive Opinion for Imsidolimab in GPP
Thursday, July 23, 2026
🇺🇸 FDA

H1-antihistamines News

🇺🇸 FDA ← All news

FDA H1-antihistamines coverage for business development, investment, and market access teams

Critical impact AnalysisJun 7, 2026

Novartis remibrutinib wins Phase 3 in CSU: what it means

chronic spontaneous urticaria · 9 min

Sarah Chen
Critical impact AnalysisJun 7, 2026

Novartis remibrutinib wins Phase 3 in chronic spontaneous urticaria

chronic spontaneous urticaria · 8 min

Michael Rodriguez

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.